RIPK3-IN-1 is a type II DFG-out inhibitor with primary activity against RIPK3. It also demonstrates inhibitory effects on RIPK1, RIPK2, and c-Met kinase. Additionally, it inhibits ABL, BRAF/V599E, MAP4K3, and SRC kinases.
- Inhibits RIPK3 with an IC50 of 9.1 nM
- Inhibits RIPK1 with an IC50 of 5.5 μM
- Inhibits RIPK2 with an IC50 of >10 μM
- Inhibits c-Met kinase with an IC50 of 1.1 μM
- Inhibits ABL with an IC50 of 0.37 μM
- Inhibits BRAF/V599E with an IC50 of 0.15 μM
- Inhibits MAP4K3 with an IC50 of 0.012 μM
- Inhibits SRC with an IC50 of 0.075 μM